Discovery of once-weekly, peptide-based selective GLP-1 and cholecystokinin 2 receptors co-agonists - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35594964/
A group of long-acting, peptide-based, and selective GLP-1R/CCK-2R dual agonists were identified by rational design. Guided by sequence analysis, structural elements of the CCK-2R agonist moiety were engineered into the...
Lipoprotein (a) and diabetes mellitus - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35606077/
Lp(a) and diabetes are both known and established risk factors for the development of cardiovascular disease. However, studies trying to link both risk factors find an inverse association between Lp(a)...
Conclusion/Relevance: Only part of the observed association of Lp(a) with diabetes can likely be explained by causality and may also be driven by reverse causation, co-morbidities, or medications. Furthermore, this review also summarizes the role of Lp(a) within patients with diabetes. Several studies suggest that elevated Lp(a) is a causal...
Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): a randomized, open-label, multinational, phase 3b trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35546450/
doi: 10.1111/dom.14765. Online ahead of print. 1 Centre for Internal Medicine I, Marienhospital, Stuttgart, Germany. 2 Novo Nordisk A/S, Søborg, Denmark. 3 Department of Internal Diseases Diabetology and Cardiometabolic Diseases,...
Conclusions: In this basal-insulin-treated population, OW semaglutide improved glycemic control to a greater extent than TID IAsp and provided numerically greater weight loss
Comparison of Beneficial Metabolic Effects of Liraglutide and Semaglutide in Male C57BL/6J Mice
Source : https://www.canadianjournalofdiabetes.com/article/S1499-2671(21)00232-X/fulltext
Semaglutide and liraglutide are glucagon-like peptide-1 (GLP-1)-based diabetes drugs. Semaglutide possesses a longer half-life. Utilizing relatively lower doses, we compared the beneficial metabolic effects of these 2 drugs in mice...
Conclusions: Liraglutide, but not semaglutide, increased hepatic FGF21 protein level, whereas semaglutide had a greater effect on attenuating hyperleptinemia. Thus, these 2 GLP-1–based diabetes drugs may target metabolic organs, including liver and adipose tissue, with differing levels of efficacy.
-
Dr Hamid4yrArticle mentions that HD semaglutide showed an even better effect on attenuating hyperleptinemia